Intersect ENT's mission is to advance clinically proven therapy solutions that enable ear, nose, and throat (ENT) physicians to solve clinical challenges and improve the quality of life for patients.

Located in Palo Alto, CA, Intersect ENT's initial focus is chronic sinusitis, a condition that affects one out of seven adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain.1,15 For these chronic sinus sufferers, their condition deeply impacts their quality of life and often requires a complex combination of medical and surgical therapy. While surgical solutions relieve symptoms in many patients, disease can recur even in the postoperative period; the majority have symptoms that persist within the first year; 25% require another surgery.16 We at Intersect ENT believed there had to be a better way -- to improve both the patient experience and surgical outcomes as well as alleviate physician frustration with disease recurrence. We developed the PROPEL™ steroid-releasing implant with these goals in mind.

PROPEL props open the ethmoid sinus cavity following surgery and allows for localized delivery of steroid directly to the sinus mucosa, as it dissolves. For patients, this may mean less invasive treatment options, improved surgical outcomes, and reduced need for systemic drugs such as oral steroids which can lead to serious side effects.

The company holds seventeen issued U.S. patents and more than 75 patents and pending applications worldwide. Intersect ENT is backed by Kleiner, Perkins, Caufield & Byers; U.S. Venture Partners; PTV Sciences; and Medtronic.